GE Healthcare's Flyrcado Adoption Faces Headwinds, UBS Says

MT Newswires Live00:46

GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.

The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.

The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.

UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.

Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.

Price: 64.17, Change: +0.97, Percent Change: +1.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652425066?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652425066","market":"us","top_or_hot":-1,"title":"GE Healthcare's Flyrcado Adoption Faces Headwinds, UBS Says","media":"MT Newswires Live","content":"<html><body><p> GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.</p><p>The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.</p><p>The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.</p><p>UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.</p><p>Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.</p><p>Price: 64.17, Change: +0.97, Percent Change: +1.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE Healthcare's Flyrcado Adoption Faces Headwinds, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE Healthcare's Flyrcado Adoption Faces Headwinds, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-17 00:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.</p><p>The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.</p><p>The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.</p><p>UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.</p><p>Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.</p><p>Price: 64.17, Change: +0.97, Percent Change: +1.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2652425066","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652425066","pubTimestamp":1784220411,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GE Healthcare Technologies  expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.Price: 64.17, Change: +0.97, Percent Change: +1.53","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","DFEN":"Direxion Daily Aerospace & Defense Bull 3X Shares","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","NATO":"Themes Transatlantic Defense ETF","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","BK4137":"综合支持服务","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","EXI":"全球工业ETF-iShares","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4187":"航天航空与国防","ITA":"iShares Dow Jones U.S. Aerospace","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LABU":"三倍做多标普生物-Direxion","XBI":"SPDR S&P Biotech ETF","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4543":"AI","BK4501":"段永平概念","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","BK4585":"ETF&股票定投概念","UXI":"ProShares Ultra Industrials","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4566":"资本集团","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","XAR":"SPDR S&P Aerospace & Defense ETF","XLV":"健康照护类股ETF-SPDR","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","GEHC":"GE HEALTHCARE TECHNOLOGIES INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","PPA":"国防航太ETF-PowerShares","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","HCSG":"Healthcare Svcs Group Inc","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","GE":"GE航空航天","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","BK4588":"碎股","MISL":"First Trust Indxx Aerospace & Defense ETF"},"translate_title":"瑞银表示，GE Healthcare 采用 Flyrcado 面临阻力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LGHT":0.6,"NATO":0.6,"GEHC":1,"XLV":1.5,"PPA":0.6,"UXI":0.6,"HCSG":1.5,"GE":1.5,"ITA":0.6,"MISL":0.6,"XAR":0.6,"DFEN":0.6,"EXI":0.6,"LABU":0.6},"content_text":"GE Healthcare Technologies (GEHC) expects Flyrcado imaging agent sales of $500 million by 2028, but a slower-than-expected launch has weakened buy-side confidence in the product, UBS Securities said.The adoption of the Flyrcado tracer, used to diagnose coronary artery disease, is being limited by radiopharmacy investment requirements, hospital switching costs and uncertainty over future reimbursement, analysts wrote in a Wednesday research report.The investment firm said the shares are reasonably priced but expects the challenges around Flyrcado to slow adoption and leave its earnings estimates below consensus from 2027 onward.UBS reiterated its neutral rating on the stock and cut its price target to $67 per share from $69.Shares of GE Healthcare were up 1.5% in Thursday afternoon trading.Price: 64.17, Change: +0.97, Percent Change: +1.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652425066","isCrawlerRequest":true}